Cipla Ltd.

Cipla has inked an investment pact with FIL Capital Investments (Mauritius) II for its consumer healthcare business. The investment is subject to approvals from the Foreign Investment Promotion Board (FIPB) and the Competition Commission of India (CCI), and the transfer of Cipla’s consumer healthcare business to Cipla Health.

In July, Cipla’s board had approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FIL Capital Investments (Mauritius) II or its affiliates in its recently launched consumer healthcare business.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.